At a glance
- Originator Taisho Pharmaceutical
- Class Antiplatelets; Small molecules; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 23 Sep 1998 No-Development-Reported for Thrombosis in Japan (Unknown route)
- 06 Nov 1996 New profile
- 06 Nov 1996 Preclinical development for Thrombosis in Japan (Unknown route)